BioLineRx Net Income from 2010 to 2026

Stocks . USA . 
Stock . BioLineRx
BLRX Stock  USD 2.67  0.01  0.38%   
BioLineRx's shows a shrinking structural trend supported by multi-year data. Financial forecasts anticipate softening toward approximately -8.7 M. Regression distribution of quarterly values from 2010 to 2026 reveals a coefficient of variation of -58.94 . with significance of 0.84 . View All Fundamentals
 
Net Loss  
 First Reported
2009-12-31
 Previous Quarter
-3.9 M
 Current Value
-977 K
 Quarterly Volatility
5 M
Macro event markers
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Financial statement trends for BioLineRx provide structured context on operating performance and capital structure. This context pairs drivers like Depreciation And Amortization of 4.9 M, Gross Profit of 18.6 M or Other Operating Expenses of 29.6 M and ratios such as Price To Sales Ratio of 0.81, Dividend Yield of 0.0 or PTB Ratio of 1.81 with BioLineRx Valuation and Volatility views.
  
Build AI portfolio with BioLineRx Stock
BioLineRx Correlation provides competitor comparison context for BioLineRx. The view supports competitor context.
Our How to Buy BioLineRx Stock guide explains the steps to invest in BioLineRx stock.
Analyzing BioLineRx's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing BioLineRx's current valuation and future prospects.

Latest BioLineRx's Net Income Growth Pattern

Below is the plot of the Net Income of BioLineRx over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in BioLineRx financial statement analysis. It represents the amount of money remaining after all of BioLineRx operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is BioLineRx's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioLineRx's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported -9.22 M10 Years Trend
Very volatile
Compare to OthersAll Fundamentals
   Net Income   
       Timeline  

BioLineRx Net Income Regression Statistics

Arithmetic Mean-21,491,328
Coefficient Of Variation-58.94
Mean Deviation 8,885,793
Median-20,415,210
Standard Deviation 12,666,459
Sample Variance160.4T
Range52.3M
R-Value-0.05
Mean Square Error170.7T
R-Squared 0.0027
Significance 0.84
Slope-130,485
Total Sum of Squares2567T

BioLineRx Net Income History

2026-8.7 M
2025-8.3 M
2024-9.2 M
2023-60.6 M
2022-25 M
2021-27.1 M
2020-30 M

Other Fundumenentals of BioLineRx

Net Income Applicable To Common Shares
Net Income From Continuing Ops
Net Income Per Share
Net Income Per E B T

BioLineRx Net Income component correlations

Click cells to compare fundamentals

Stock Overview, Methodology & Data Sources

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modiin, Israel. Biolinerx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 38 people. As a micro-cap equity, BioLineRx is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/B of 0.59, profit margin of -45.34%. BioLineRx has a market cap of 15.18 M, ROE of -45.94%.

Methodology

Unless otherwise specified, financial data for BioLineRx is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. BioLineRx (USA Stocks:BLRX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: Macroaxis analytics incorporate public filings and market reference sources and official disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Data harmonization may result in minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

BioLineRx is covered by 2 analysts. 1 analyst has submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Evercore ISI, Morgan Stanley, BMO Capital Markets, Oppenheimer & Co., Guggenheim Securities, among others. Updates may occur throughout the day.

This content is curated and reviewed by:

Gabriel Shpitalnik - Member of Macroaxis Editorial Board

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
MSFTMicrosoft
CCitigroup
WDWalker Dunlop

More Resources for BioLineRx Stock Analysis

Reviewing BioLineRx commonly begins with financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends. Selected reports below provide context for BioLineRx Stock:
How To Invest In BioLineRx
Details
Is BioLineRx Stock a good investment?
Details
What is BioLineRx's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
BioLineRx Correlation provides competitor comparison context for BioLineRx. The view supports competitor context.
Our How to Buy BioLineRx Stock guide explains the steps to invest in BioLineRx stock.
Analysis related to BioLineRx should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
 Earnings Share
-6.00
 Revenue Per Share
6
 Quarterly Revenue Growth
-0.94
 Return On Assets
-0.15
 Return On Equity
-0.46
Investors evaluate BioLineRx using market value and book value, each describing different facets of the business. BioLineRx's market capitalization is 15.18 M. A P/B ratio of 0.59 suggests BioLineRx trades near or below book value. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Valuation work aligns these measures into a single context.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Analysis
Details
Earnings
Projections
Details
The concept of value for BioLineRx differs from its quoted price, since each reflects a different lens. For BioLineRx, key inputs include a P/B ratio of 0.59, a profit margin of -45.34%, ROE of -45.94%, and revenue of 28.94 M. Trading price represents the transaction level agreed by market participants.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY